This activity was originally broadcast live at AJMC® Day of Education Spring 2023.
Program Description
The use of immune checkpoint inhibitors (ICIs) has transformed the treatment paradigm for patients with advanced or metastatic non-small cell lung cancer (NSCLC) and has led to the investigation of these therapies in early-stage disease as well. Managed care professionals must be aware of emerging data and guideline updates to ensure optimal combination and sequencing of these agents for early-stage NSCLC as well as management of toxicities. This activity will review safety and efficacy data of ICIs as neoadjuvant, adjuvant, and consolidation therapy in early-stage NSCLC as monotherapy, in combination with other ICIs or chemotherapy, and in combination with radiation therapy. The rising economic burden of cancer care cost is an increasingly important consideration for managed care pharmacists alongside clinical benefit and toxicity. Managed care professionals will gain insight into their roles in providing value-based and patient-centered care delivery models to improve patient care, increase access, and reduce or manage costs associated with ICI therapy in early-stage NSCLC.
Target audience: Managed care and oncology pharmacists
Type of activity: Application
Release date: April 27, 2023
Expiration date: April 27, 2024
Time to complete activity: 1.5 hours
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the evidence for using FDA-approved immune checkpoint inhibitors (ICIs) as neoadjuvant, adjuvant, and/or consolidation therapy in patients with early-stage non-small cell lung cancer (NSCLC).
- Apply guideline recommendations and clinical data to determine the most up-to-date, value-based treatments for patients with nonmetastatic NSCLC.
- Explore strategies to maximize the value of ICIs in the treatment sequence of early-stage NSCLC according to agent effectiveness, impact on recurrence, and cost of care.
Stefanie L. Houseknecht, PharmD, BCOP
Clinical Pharmacy Specialist, Thoracic Oncology
The Johns Hopkins Hospital and Bayview Medical Center
Baltimore, Maryland
Jacob K. Kettle, PharmD
Director, Ellis Fischel Cancer Center
University of Missouri Health Care
Columbia, Missouri
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-185-H01-P. The activity is available for CE credit through April 27, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Stefanie L. Houseknecht, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
- Consultant: Aptar Pharma
- Stock/Shareholder: Stock in Pfizer
Jacob K. Kettle, PharmD, has the following financial relationships with commercial interests to disclose:
Consultant: Genentech, Urogen
Speaker: Genentech; Amgen; Daiichi Sankyo, Inc.
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Evelina Kolychev, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms